| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2) | In curs de recrutate | Research Site, Bucharest, Romania, 022328Research Site, Bucharest, Romania, 030171Research Site, Bucharest, Romania, 050098Research Site, Bucuresti, Romania, 020125Research Site, Cluj-Napoca, Romania, 400124Research Site, Iasi, Romania, 700483Research Site, Oradea, Romania, 410469Research Site, Sibiu, Romania, 550245Research Site, Timisoara, Romania, 300079 |
| 2 | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. (CANDOR) | Activ, inca nu se recruteaza | Research Site, Brasov, Romania, 500152Research Site, Bucharest, Romania, 030171Research Site, Bucharest, Romania, 050098Research Site, Bucuresti, Romania, 020125Research Site, Bucuresti, Romania, 022328Research Site, Cluj-Napoca, Romania, 400124Research Site, Craiova, Romania, 200143 |
| 3 | Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1) | Activ, inca nu se recruteaza | Local Institution, Brasov, Romania, 500152Local Institution, Bucuresti, Romania, 030171Local Institution, Bucuresti, Romania, 020125Local Institution, Bucuresti, Romania, 050098Local Institution, Bucuresti, Romania, 22328Local Institution, Iasi, Romania, 700483 |
| 4 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON) | Activ, inca nu se recruteaza | Hyperclnical MedLife PDR Vulturului Brasov, Hematology Department, Braşov, Romania, 500366Colentina Clinical Hospital, Department of Hematology, Bucharest, Romania, 020125Bucharest University Emergency Hospital, Department of Hematology, Bucharest, Romania, 050098 |
| 5 | A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | Activ, inca nu se recruteaza | Brasov, RomaniaBucharest, RomaniaIasi, Romania |
| 6 | A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN) | Activ, inca nu recruteaza | RO-02, Braşov, RomaniaRO-01, Bucharest, Romania |
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab) | Activ, inca nu se recruteaza | Research Site, Craiova, Romania, 200385 |
| 2 | Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743) | Activ, inca nu se recruteaza | Local Institution, Bucharest, Romania, 020122Local Institution, Bucuresti, Romania, 021389Local Institution, Craiova, Romania, 200347Local Institution, Romania, Romania, 400015 |
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4) | Activ, nu se recruteaza | Sp. Judetean de Urgenta Dr. Constantin Opris Baia Mare, Baia Mare, Romania, 430031S.C. Policlinica de Diagnostic Rapid S.A., Brasov, Romania, 500152Fundeni Clinical Institute, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucharest, Romania, 030171Sp. Univ. de Urgenta Militar Central Dr. Carol Davila, Bucuresti, Romania, 010825Spitalul Clinic Colentina, Bucuresti, Romania, 020125Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania, 200143Institutul Regional de Oncologie Iasi, Iasi, Romania, 700111Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Spitalul Clinic Judetean de Urgenta Targu-Mures, Targu-Mures, Romania, 540136 |
| 2 | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-3) | Activ, inca nu se recruteaza | Brasov, Romania, 500152Bucharest, Romania, 030171Bucuresti, Romania, 010825Bucuresti, Romania, 020125Bucuresti, Romania, 022328Cluj-Napoca, Romania, 400015Craiova, Romania, 200143Targu-Mures, Romania, 540136 |
| 3 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | Activ, inca nu se recruteaza | Institut Clinic Fundeni, Bucuresti, Romania, 22328Spitalul Clinic de Urgenta pentru Copii M.S. Curie, Bucuresti, Romania, 41451Institutul Oncologic ‘Prof Dr. Ion Chiricuta’ Cluj-Napoca , Cluj-Napoca, Romania, 400015Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea, Oradea, RomaniaSpitalul Clinic de Urgenta pentru Copii ‘Louis Turcanu’, Timisoara, Romania, 300011 |
| 4 | Dose Optimization Study of Idelalisib in Follicular Lymphoma | In curs de recrutare | Spitalul Judetean de Urgenta Dr.Constantin Opris Baia Mare, Baia Mare, RomaniaSpitalul Clinic Coltea, Bucuresti, RomaniaInstitutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca, RomaniaInstitutul Regional De Oncologie IASI, Iasi, Romania |
| 5 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (ECHELON-2) | Activ, inca nu se recruteaza | Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucuresti, Romania, 030171Institutul Oncologic „Prof. Dr. I. Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular, Targu Mures, Romania, 540136 |
| 6 | Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | Activ, inca nu se recruteaza | Policlinica de Diagnostic Rapid SA, Brasov, Romania, 500152Spitalul Clinic Colentina, Bucuresti, Romania, 020125Spitalul Clinic Coltea, Bucuresti, Romania, 030171Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania, 540042 |
| 7 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND) | In curs de recrutare | MorphoSys Research Site, Bucharest, Romania, 022328MorphoSys Research Site, Bucharest, Romania, 30171MorphoSys Research Site, Iaşi, Romania, 700483 |
| 8 | Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | In curs de recrutare | Cluj NapocaIon Chiricuta Oncology Institute, Cluj Napoca, Romania, 400015 Contact: Ciprian Tomuleasa, MD 0040741337480 ciprian.tomuleasa@umfcluj.ro Contact: Catalin Vlad, MD 0040264598362 catalinvlad@yahoo.it |
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) | Activ, inca nu se recruteaza | Institutul Regional de Oncologie Iași, Iași, Romania, 20125Spitalul Clinic Colentina, Bucuresti, Romania, 20125Spitalul Clinic Coltea, Bucuresti, Romania, 20125Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania, 20125Institutul Clinic Fundeni, Bucuresti, Romania, 22328Institutul Oncologic „Prof. Dr. Ion Chiricuţă” Cluj Napoca, Cluj-Napoca, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania, 200143Spitalul Clinic Judetean de Urgenta Târgu-Mureş (4005), Târgu-Mureş, Romania, 540042Spitalul Clinic Judetean de Urgenta Târgu-Mureş (4008), Târgu-Mureş, Romania, 540136 |
| 2 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019) | Activ, inca nu se recruteaza | Institutul Oncologic ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca, Cluj, Romania, 400124Spitalul Clinic Municipal Filantropia Craiova, Sectia Clinica Hematologie, Craiova, Dolj, Romania, 200136Spitalul Universitar de Urgenta Militar Central „Dr. Carol Davila” Bucuresti, Bucuresti, Romania, 010825Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania, 030171 |
| 3 | Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia. | Acitv, inca nu se recruteaza | Novartis Investigative Site, Bucharest, District 2, Romania, 022328Novartis Investigative Site, Tg Mures, Mures, Romania, 540136Novartis Investigative Site, Craiova, Romania, 200136Novartis Investigative Site, Iasi, Romania, 700483 |
| 4 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | Activ, inca nu se recruteaza | Site RO40005, București, Romania |
| 5 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | Activ, inca nu se recruteaza | Novartis Investigative Site, Bucharest, District 2, Romania, 022328Novartis Investigative Site, Bucharest, Romania, 030171Novartis Investigative Site, Cluj-Napoca, Romania, 400124Novartis Investigative Site, Craiova, Romania, 200136Novartis Investigative Site, Timisoara, Romania, 300079 |
| 6 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL | Activ, inca nu se recruteaza | Research Site, Bucharest, Romania, 022328Research Site, Cluj-Napoca, Romania, 400177 |
| 7 | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia | In curs de recrutare | Insitutul Clinic Fundeni, Sectia de Transplant Medular, Bucharest, Romania, Contact: Anca Colita, MD PhD, ancacolita@yahoo.com Principal Investigator: Anca Colita, MD PhD University of Medicine and Pharmacy V. BABES, Emergency Children’s Hospital LOUIS TURCANU, III. Clinic of Pediatrics , Department of Onco-hematology and Bone Marrow Transplantation, Timişoara, Romania, Contact: Cristian Jinca, MD PhD, cristian_jinca@yahoo.com Principal Investigator: Cristian Jinca, MD PhD |
| 8 | A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy | Activ, inca nu se recruteaza | Institutul Clinic Fundeni, Bucharest, Romania, 022328Spitalul Clinic Coltea, Bucharest, Romania, 030171Spitalul Clinic Judetean de Urgenta Sf Spiridon Iasi , Iasi, Romania, 700111Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Spitalul Clinic Municipal de Urgenta Timisoara, Timisoara, Romania, 300079 |
| 9 | A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia | Activ, inca nu se recruteaza | Fundeni Clinical Inst. ; Hematology Dept., Bucharest, Romania, 022328Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania, 700483Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania, 540136 |
| 10 | A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib | Activ, inca nu se recruteaza | Local Institution, Bucharest, Romania, 022322 |
| 11 | Safety, Tolerability, Pharmacokinetics and Activity of K0706 | In curs de recrutare | Spitalul Clinic Colentina Recruiting Bucuresti, Romania, 020125 Spitalul Clinic Coltea Recruiting Bucuresti, Romania, 030171 Institutul Oncologic „Prof. Dr. Ion Chiricuta” Cluj-Napoca Recruiting Cluj-Napoca, Romania, 400124 Spitalul Clinic Municipal Filantropia Craiova Recruiting Craiova, Romania, 200143 Spitalul Clinic Judetean de Urgenta Targu Mures Recruiting Târgu Mureș, Romania, 540136 |
| 12 | An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL | In curs de recrutare | Spitalul Clinic Municipal de Urgenta Timisoara Recruiting Timisoara, Timis, Romania, 300021 Spitalul Clinic Colentina Recruiting Bucuresti, Romania, 020125 Spitalul Universitar de Urgenta Bucuresti Recruiting Bucuresti, Romania, 50098 Institutul Regional de Oncologie Iasi Recruiting Iasi, Romania, 700483 |
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX) | In curs de recrutare | Local Institution, Brasov, Romania, 500091, Contact: Site 0060 Local Institution, Bucharest, Romania, 022328, Contact: Site 0078 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0232 Local Institution, Constanta, Romania, 900591, Contact: Site 0242 Local Institution, Craiova, Romania, 200347, Contact: Site 0074 S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Romania, 300166, Contact: Roxana-Ioana Scheusan, Site 0070 +40745146020 |
| 2 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL) | Activ, inca nu se recruteaza | Cluj-Napoca, Cluj, Romania, 400015Brasov, Romania, 500019 |
| 3 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW) | In curs de recrutare | Local Institution, Craiova, Dolj, Romania, 200347, Contact: Site 0103 Local Institution, Bucharest, Romania, 22328, Contact: Site 0164 Local Institution, Cluj Napoca, Romania, 400015, Contact: Site 0165 Local Institution, Craiova, Romania, 200385, Contact: Site 0208 Local Institution, Timisoara, Romania, 300166, Contact: Site 0163 |
| 4 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | Activ, inca nu se recruteaza | Spitalul Pelican Impex SRL- Sectia Oncologie Medicala, Bihor, RomaniaInstitutul Clinic Fundeni – Sectia Oncologie Medicala, Bucuresti, RomaniaClinica Bendis – Oncologie Medicala, Cluj, RomaniaCentrul de Oncologie ONCOLAB, Dolj, RomaniaInstitutul Regional de Oncologie Iasi – Sectia Oncologie Medicala, Iaşi, RomaniaSC DACMED SRL – Oncologie, Prahova, RomaniaSpitalului Clinic Judetean de Urgenta – Sectia Oncologie Medicala, Sibiu, RomaniaSpitalul Judetean de Urgenta „Sf. Ioan Cel Nou” – sectia Oncologie Medicala, Suceava, Romania |
| 5 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312) | In curs de recrutare | Exelixis Clinical Site #204 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400015 Exelixis Clinical Site #211 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400015 Exelixis Clinical Site #202 Active, not recruiting Cluj-Napoca, Cluj, Romania, 400641 Exelixis Clinical Site #206 Active, not recruiting Bucuresti, Romania, 022328 Exelixis Clinical Site #209 Active, not recruiting Iaşi, Romania, 700483 |
| 6 | Contrast Enhanced Ultrasound Guidance Biopsy for the Diagnosis of Liver Tumors (ConCLUDe) | In curs de recrutare | Regional Institute of Gastroenterology and Hepatology „Octavian Fodor” Recruiting Cluj-Napoca, Please Enter The State Or Province, Romania, 400126 Contact: Tudor Mocan +40 799 861946 Mocan.Tudor@umfcluj.ro Contact: Ioana Rusu ioana.russu@yahoo.com |
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Surgery for Recurrent Glioblastoma (RESURGE) | In curs de recrutare | Department of Neurosurgery, Spitalul Clinic De Urgență „Bagdasar-Arseni” , Bucharest, Romania, 041915, Contact: George Petrescu, MD |
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy. | Activ, inca nu recruteaza | SC Oncolab SRL, Craiova, Dolj, Romania, 200385S.C. Oncocenter Oncologie Clinica S.R.L., Timisoara, Timis, Romania, 300166SC ONCOCENTER Oncologie Clinica SRL, Timisoara, Timis, Romania, 300210Spitalul Clinic C.F. 2 Bucuresti. Departament Oncologie, Sectia Medicala 2, Bucuresti, Romania, 011464 |
| 2 | Pan Tumor Nivolumab Rollover Study | In curs de recrutare | Local Institution, Bucharest, Romania, 022328, Contact: Site 0129 Local Institution, Cluj Napoca, Romania, 400015, Contact: Site 0135 Local Institution, Cluj Napoca, Romania, 400641, Contact: Site 0127 Local Institution, Oradea, Romania, 440445, Contact: Site 0133 |
| 3 | A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848) | In curs de recrutare | Local Institution, Bucuresti, Romania, 022328Local Institution, Cluj-Napoca, Romania, 400015Local Institution, Craiova, Romania, 200347Local Institution, Floresti, Romania, 407280Local Institution, Timisoara, Timis, Romania, 300239 |
| 4 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | Activ, inca nu recruteaza | S.C Delta Health Care S.R.L, Bucuresti, Romania, 014142S.C Medisprof S.R.L., Cluj-Napoca, Romania, 400641S.C Centrul de Oncologie Sf. Nectarie S.R.L., Craiova, Romania, 200347S.C Oncocenter Oncologie Clinica S.R.L., Timişoara, Romania, 300166 |
| 5 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | In curs de recrutare | S.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102), Oradea, Bihor, Romania, 410469, Contact: Study Coordinator +40746103306 SC Radiotherapy Center Cluj SRL ( Site 1105), Comuna Floresti, Cluj, Romania, 407280, Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103), Craiova, Dolj, Romania, 200347, Contact: Study Coordinator +40727774974 Spitalul PDR Medlife ( Site 1106), Brasov, Romania, 500152, Contact: Study Coordinator +40722559551 S.C.Focus Lab Plus S.R.L ( Site 1101), Bucuresti, Romania, 021389, Contact: Study Coordinator +40721298677 S.C.Gral Medical S.R.L ( Site 1104), Bucuresti, Romania, 031422, Contact: Study Coordinator +40723954705 Medisprof ( Site 1107), Cluj Napoca, Romania, 400641, Contact: Study Coordinator +40751274636 |
| 6 | Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer | In curs de recrutare | Research Site, Bucharest, Romania, 022328Research Site, Cluj-Napoca, Romania, 400015Research Site, Cluj-Napoca, Romania, 400124Research Site, Timisoara, Romania, 300239 |
| 7 | An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | In curs de recrutare | Local Institution, Bucharest, Romania, 022328, Contact: Site 0045 Local Institution, Craiova, Romania, 200347, Contact: Site 0041 |
| 8 | A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | In curs de recrutare | Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania, 400015Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania, 400015ONCOMED – Medical Centre, Timisoara, Romania, 300239 |
| 9 | Durvalumab Long-Term Safety and Efficacy Study (WAVE) | In curs de recrutare | Research Site, Craiova, Romania, 200347Research Site, Suceava, Romania, 720237 |
| 10 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) | In curs de recrutare | Centrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347 |
| 11 | Avelumab Program Rollover Study | In curs de recrutare | Spitalul Clinic Municipal „Dr. Gavril Curteanu” Oradea – Centrul Oncologie Medicala, Oradea, Romania, 410469, Contact: simonamihutiu@yahoo.com, Principal Investigator: Simona Mihutiu |
| 12 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | Activ, inca nu recruteaza | Novartis Investigative, Bucuresti, Romania, 011863 |
| 13 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV) | Activ, inca nu se recruteaza | Emergency Clinical County Hospital Brasov, Brasov, RomaniaBucharest University Emergency Hospital, Bucharest, RomaniaColtea Clinical Hospital, Bucharest, Romania |
| 14 | A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS) | In curs de recrutare | Fundeni CLinical Institute, Clinic of Hematology, Bucharest, Romania |
| 15 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | Activ, inca nu se recruteaza | Institutul Oncologic Bucuresti Bucharest, Romania Spitalului Universitar de Urgenta Militar Central Bucharest, Romania Amethyst-Cluj Floresti, Romania County Hospital ‘Dr Gavril Curteanu’ Oradea, Romania County Hospital, Targu Mures Targu Mures, Romania Municipal Emergency Hospital Timisoara, Romania |
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | Activ, inca nu se recruteaza | Oncomed SRL, Timisoara, JUD. Timis, Romania, 300239Institutul Oncologic „Prof.Dr.I.Chiricuta” Cluj-Napoca, Cluj-Napoca, Romania, 400015 |
| 2 | An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer | In curs de recrutare | Bucharest, RomaniaCluj-Napoca, RomaniaCraiova, RomaniaIasi, Romania |
| 3 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | Activ, inca nu se recruteaza | „Prof. Dr. Ion Chiricuta” Oncology Institute, Cluj-Napoca, Romania, 400015S.C. Medisprof S.R.L., Cluj-Napoca, Romania, 400641″Sfantul Nectarie” Oncology Center, Craiova, Romania, 200347Oncomed SRL, Timisoara, Romania, 300239 |
| 4 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) | In curs de recrutare | Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0191 Local Institution, Craiova, Romania, 200347, Contact: Site 0187 |
| 5 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | Activ, inca nu se recruteaza | Oncopremium Team Srl, Baia Mare, Romania, 430291Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter, Cluj-Napoca, Romania, 400015Centrul de Oncologie Sfantul Nectarie, Craiova, Romania, 200347Centrul de Radioterapie AMETHYST, Floresti, Romania, 407280Oncomed SRL; Oncologie, Timisoara, Romania, 300239 |
| 6 | An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274) | Activ, inca nu se recruteaza | Local Institution, Bucuresti, Romania, 021389Local Institution, Craiova, Romania, 200347Local Institution, Floresti, Romania, 407280Local Institution, Timisoara, Timis, Romania, 300239 |
| 7 | A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC | In curs de recrutare | Institute Of Oncology „Prof.Dr.Alexandru Trestioreanu” Bucharest, Bucharest, Romania, 020122, Contact: Aurelia Alexandru, Site 0058 Local Institution, Craiova, Romania, 200347, Contact: Site 0076 |
| 8 | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal) | In curs de recrutare | County Hospital Alba; Oncology, Alba Iulia, Romania, 510073Centrul Medical Focus; Oncologie medicala, Bucharest, Romania, 021389University Clinical Emergency Hospital Bucharest, Bucharest, RomaniaInstitutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania, 022328Sanador Medical Center; Medical Oncology, Bucuresti, RomaniaSpitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, Romania, 900591Institutul Regional de Oncologie Iasi, Iasi, Romania, 700483Spitalul Municipal Ploiesti, Ploiesti, Romania, 100337Oncomed SRL; Oncologie, Timisoara, Romania, 300239Oncocenter Timisoara , Timişoara, Romania, 300166 |
| 9 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE) | Activ, inca nu se recruteaza | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician. Baia Mare, Romania, 430110Cluj-Napoca, Romania, 400058Craiova, Romania, 200347 |
| 10 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914) | In curs de recrutare | Local Institution, Bucharest, Romania, 50659, Contact: Site 0201 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0200 Local Institution, Craiova, Romania, 200347, Contact: Site 0199 Local Institution, Lasi, Romania, 700483, Contact: Site 0202 |
| 11 | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Activ, inca nu se recruteaza | Local Institution, Bucharest, Romania, 014142, Contact: Site 0076 Local Institution, Bucharest, Romania, 020122, Contact: Site 0061 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0056 Local Institution, Constanta, Romania, 900591, Contact: Site 0059 Local Institution, Craiova, Romania, 200347, Contact: Site 0065 |
| 12 | Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130) | Activ, inca nu se recruteaza | Spitalul Judetean de Urgenta Dr Constantin Opris, Baia Mare, Romania, 430031Institute Of Oncology Bucharest; Medical Oncology, Bucharest, Romania, 022338Oncology Center Sf. Nectarie, Craiova, Romania, 200347 |
| 13 | Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma | Activ, inca nu se recruteaza | Medisprof SRL, Cluj-Napoca, RomaniaProf Dr I Chiricuta Institute of Oncology, Cluj-Napoca, RomaniaOncology Center Sfantul Nectarie, Craiova, RomaniaOncocenter Clinical Oncology, Timisoara, Romania |
| 14 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) | Activ, inca nu se recruteaza | Instit. Prof.Dr.Ion Chiricuta, Cluj-Napoca, Romania, 400015Sf. Nectarie Oncology Center, Craiova, Romania, 200347 |
| 15 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | In curs de recrutare | Centrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania, 200347Oncolab SRL, Craiova, Dolj, Romania, 200385Medisprof SRL , Cluj-Napoca, Romania, 400461Clinical Emergency Hospital of Constanta, Constanta, Romania, 900591Center of Oncology Euroclinic, Iasi, Romania, 700106Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Oncocenter – Oncologie Clinica SRL, Timisoara, Romania, 300166 |
| 16 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | In curs de recrutare | Spitalul Clinic Judetean de Urgenta ‘Sf Apostol Andrei’ Constanta Not yet recruiting Constanta, Romania, 900591 |
| 17 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Activ, nu se recruteaza | Local Institution Bucharest, Romania, 020122 Local Institution Cluj-Napoca, Romania, 400015 Local Institution Constanta, Romania, 900591 Local Institution Craiova, Romania, 200347 |
| 18 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | Activ, nu se recruteaza | Local Institution Bucharest, Romania, 022328 Local Institution Craiova, Romania, 200385 Local Institution Iasi, Romania, 700106 Local Institution Timisoara, Romania, 300167 |
| 19 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) | In curs de recrutare | Local Institution Not yet recruiting Bucharest, Romania, 022328 Contact: Site 0039 Local Institution Not yet recruiting Cluj-Napoca, Romania, 400015 Contact: Site 0014 Local Institution Not yet recruiting Craiova, Romania, 200347 Contact: Site 0013 |
| 20 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | In curs de recrutare | S.C. Radiotherapy Center Cluj S.R.L ( Site 0252) Recruiting Cluj-Napoca, Cluj, Romania, 407280 Contact: Study Coordinator +40742206212 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248) Recruiting Craiova, Dolj, Romania, 200347 Contact: Study Coordinator +40722161545 |
| Nr. | Numelestudiului | Status | Locatia/Locatiilestudiului |
| 1 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | In curs de recrutare | Local Institution, Bucharest, Romania, 022328, Contact: Site 0066 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0070 Local Institution, Craiova, Romania, 200347, Contact: Site 0067 Local Institution, Lasi, Romania, 700483, Contact: Site 0069 |
| 2 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | In curs de recrutare | Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0070 Local Institution, Craiova, Romania, 200347, Contact: Site 0071 Local Institution, Floresti, Romania, 407280, Contact: Site 0120 Local Institution, Oradea, Romania, 410469, Contact: Site 0073 |
| 3 | Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) | In curs de recrutare | Local Institution, Bucharest, Romania, 020122, Contact: Site 0021 Local Institution, Cluj-Napoca, Romania, 400015, Contact: Site 0047 Local Institution, Craiova, Romania, 200347, Contact: Site 0020 |
| 4 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915) | Activ, inca nu se recruteaza | Institute Of Oncology „Prof.Dr.Alexandru Trestioreanu” Bucharest, Bucharest, Romania, 022328Sf. Nectarie Oncology Center, Craiova, Romania, 200347 |
| 5 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) | Activ, inca nu se recruteaza | Local Institution, Craiova, Romania, 200347Local Institution, Romania, Romania, 400015 |
| 6 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | In curs de recrutare | Nova Clin Medical Research Center, Timisoara, Romania, 300696, Contact: Alexandru Bolocan, Site 0030 |
| 7 | Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | In curs de recrutare | Spitalul Universitar CF Cluj-Napoca ( Site 1103) RecruitingCluj-Napoca, Cluj, Romania, 400015, Contact: Study Coordinator +40724283983 S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1101), Craiova, Dolj, Romania, 200347, Contact: Study Coordinator +40727774974 S C Oncocenter Oncologie Medicala S R L (Site 1106), Timisoara, Timis, Romania, 300166, Contact: Study Coordinator +40745146020 Hifu Terramed Conformal SRL ( Site 1111), Bucharest, Romania, 031864, Contact: Study Coordinator +40723599588 S.C.Focus Lab Plus S.R.L ( Site 1107), Bucuresti, Romania, 021389, Contact: Study Coordinator +40721298677 Cardiomed SRL Cluj-Napoca ( Site 1104), Cluj-Napoca, Romania, 400015, Contact: Study Coordinator +40724543672 S C Pelican Impex SRL ( Site 1108), Oradea, Romania, 410450, Contact: Study Coordinator +40746103306 Policlinica Oncomed SRL ( Site 1105), Timisoara, Romania, 300239, Contact: Study Coordinator +40744571617 |
| 8 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Activ, inca nu se recruteaza | Centrul de Oncologie Sfantul Nectarie, Craiova, Dolj, Romania, 200347Oncolab SRL, Craiova, Dolj, Romania, 200385Medisprof SRL , Cluj-Napoca, Romania, 400461Clinical Emergency Hospital of Constanta, Constanta, Romania, 900591Center of Oncology Euroclinic, Iasi, Romania, 700106Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania, 550245Oncocenter – Oncologie Clinica SRL, Timisoara, Romania, 300166 |
| Nr. | Numele studiului | Status | Locatia/Locatiile studiului |
| 1 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) | In curs de recrutare | Bucharest, Romania, 10825, Contact: Contact 1-888-EXELIXIS (888-393-5494) Bucharest, Romania, 11863, Contact: Contact 1-888-EXELIXIS (888-393-5494) Cluj-Napoca, Romania, 400058, Contact: Contact 1-888-EXELIXIS (888-393-5494) Cluj-Napoca, RomaniaTimisoara, Romania, 300723 |
| 2 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy | In curs de recrutare | Exelixis Clinical Site #149, Cluj-Napoca, Cluj, Romania, 400015Exelixis Clinical Site #150, Craiova, Dolj, Romania, 200385Exelixis Clinical Site #142, Timişoara, Timis, Romania, 300166Exelixis Clinical Site #146, Bucuresti, Romania, 011863 |
| 3 | A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Activ, inca nu se recruteaza | Facility #1, Cluj-Napoca, Cluj, Romania, 400058Facility #1, Bucharest, Romania, 11863 |
| 4 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | Activ, inca nu se recruteaza | Investigational Site Number 1801, Bucharest, Romania |